The Cortisol Response to Hypobaric Hypoxia at Rest and Post-Exercise

 

 Buy Article Permissions and Reprints

Abstract

High altitude exposure normally leads to a marked natriuresis and diuresis. Acute mountain sickness is often associated with fluid retention, to which an elevated cortisol may contribute. Most investigators report a rise in resting cortisol with ascent, but little data exist regarding the cortisol response to a day trekking. We therefore measured salivary cortisol during ascent to >5 000 m in a cohort of between 42–45 subjects following a 6-h trek (samples taken between 15:30–16:30 h) and between 15–20 subjects at rest (morning samples taken between 08:00–09:00 h). Morning resting cortisol [nmol/l, mean±sd, (range)] was 5.5±2.9 (2.13–13.61) at 1 300 m; 4.7±6.8 (1.4–27.02) at 3 400 m, and significantly (p=0.002) rose between 4 270 m [3.5±2.1 (1.4–8.34)] and 5 150 m [14.5±30.3 (1.9–123.1)]. Post-exercise cortisol [nmol/l, mean±sd, (range)] dropped between 3 400 m [7±6 (1.5–33.3)] and 4 270 m [4.2±4.8 (1.4–29.5)] (p=0.001) followed by a significant rise in post-exercise cortisol between 4 270 m [4.2±4.8 (1.4–29.5)] and 5 150 m [9.2±10.2 (1.4–61.3)] (p<0.001). There were no significant associations between severity of acute mountain sickness and cortisol levels. There was a significant though weak correlation between cortisol post-exercise at 5 150 m and oxygen saturation at 5 150 m (rho= − 0.451, p=0.004). In conclusion, this is the largest cohort to have their resting and post-exercise cortisol levels ascertained at high altitude. We confirm the previous findings of an elevated resting morning cortisol at >5 000 m, but present the novel finding that the cortisol response to a day trekking at HA appears suppressed at 4 270 m.

• References

• 1 Bartsch P, Maggiorini M, Schobersberger W, Shaw S, Rascher W, Girard J, Weidmann P, Oelz O. Enhanced exercise-induced rise of aldosterone and vasopressin preceding mountain sickness. J Appl Physiol 1991; 71: 136-143
  PubMedGoogle Scholar
• 2 Zaccaria M, Rocco S, Noventa D, Varnier M, Opocher G. Sodium regulating hormones at high altitude:basal and post-exercise levels. J Clin Endocrin Metab 1998; 83: 570-574
  CrossrefPubMedGoogle Scholar
• 3 Loeppky JA, Icenogle MV, Maes D, Riboni K, Hinghofer-Szalkay H, Roach RC. Early fluid retention and severe acute mountain sickness. J Appl Physiol 2005; 98: 591-597
  PubMedGoogle Scholar
• 4 Maggiorini M, Buhler B, Walter M, Oelz O. Prevalence of acute mountain sickness in the Swiss Alps. BMJ 1990; 301: 853-855
  CrossrefPubMedGoogle Scholar
• 5 Hackett PH, Rennie D, Hofmeister SE, Grover RF, Grover EB, Reeves JT. Fluid retention and relative hypoventilation in acute mountain sickness. Respiration 1982; 43: 321-329
  CrossrefPubMedGoogle Scholar
• 6 Ramirez G, Bittle PA, Hammond M, Ayers CW, Dietz J, Colice GL. Regulation of aldosterone secretion during hypoxiemia at sea level and moderately high altitude. J Clin Endocrinol Metab 1988; 67: 1162-1165
  CrossrefPubMedGoogle Scholar
• 7 McLean CJ, Booth CW, Tattersall T, Few JD. The effect of high altitude on saliva aldosterone and glucocorticoid concentrations. Eur J Appl Physiol Occup Physiol 1989; 58: 341-347
  CrossrefPubMedGoogle Scholar
• 8 Di Luigi L, Baldari C, Sgrò P, Emerenziani GP, Gallotta MC, Bianchini S, Romanelli F, Pigozzi F, Lenzi A, Guidetti L. The type 5 phosphodiesterase inhibitor tadalafil influences salivary cortisol, testosterone, and dehydroepiandrosterone sulphate responses to maximal exercise in healthy men. J Clin Endocrinol Metab 2008; 93: 3510-3514
  CrossrefPubMedGoogle Scholar
• 9 VanBruggen MD, Hackney AC, McMurray RG, Ondrak KS. The relationship between serum and salivary cortisol levels in response to different intensities of exercise. Int J Sports Physiol Perform 2011; 6: 396-407
  PubMedGoogle Scholar
• 10 Nunes JA, Crewther BT, Ugrinowitsch C, Tricoli V, Viveiros L, de Rose Jr D, Aoki MS. Salivary hormone and immune responses to three resistance exercise schemes in elite female athletes. J Strength Cond Res 2011; 25: 2322-2327
  CrossrefPubMedGoogle Scholar
• 11 Usui T, Yoshikawa T, Orita K, Ueda SY, Katsura Y, Fujimoto S, Yoshimura M. Changes in salivary antimicrobial peptides, immunoglobulin A and cortisol after prolonged strenuous exercise. Eur J Appl Physiol 2011; 111: 2005-2014
  CrossrefPubMedGoogle Scholar
• 12 Sutton JR, Viol GW, Gray GW, McFadden M, Keane PM. Renin, aldosterone, electrolyte, and cortisol responses to hypoxic decompression. J Appl Physiol 1977; 43: 421-424
  PubMedGoogle Scholar
• 13 Humpeler E, Skrabal F, Bartsch G. Influence of exposure to moderate altitude on the plasma concentration of cortisol, aldosterone, renin, testosterone, and gonadotropins. Eur J Appl Physiol 1980; 45: 167-176
  CrossrefPubMedGoogle Scholar
• 14 Richalet JP, Rutgers V, Bouchet P, Rymer JC, Kéromès A, Duval-Arnould G, Rathat C. Diurnal variations of acute mountain sickness, colour vision, and plasma cortisol and ACTH at high altitude. Aviat Space Environ Med 1989; 60: 105-111
  PubMedGoogle Scholar
• 15 Sawhney RC, Malhotra AS, Singh T. Glucoregulatory hormones in man at high altitude. Eur J Appl Physiol Occup Physiol 1991; 62: 286-291
  CrossrefPubMedGoogle Scholar
• 16 Anand IS, Chandrashekhar Y, Rao SK, Malhotra RM, Ferrari R, Chandana J, Ramesh B, Shetty KJ, Boparai MS. Body fluid compartments, renal blood flow, and hormones at 6,000 m in normal subjects. J Appl Physiol 1993; 74: 1234-1239
  PubMedGoogle Scholar
• 17 Martignoni E, Appenzeller O, Nappi RE, Sances G, Costa A, Nappi G. The effects of physical exercise at high altitude on adrenocortical function in humans. Funct Neurol 1997; 12: 339-344
  PubMedGoogle Scholar
• 18 Barnholt KE, Hoffman AR, Rock PB, Muza SR, Fulco CS, Braun B, Holloway L, Mazzeo RS, Cymerman A, Friedlander AL. Endocrine responses to acute and chronic high-altitude exposure (4 300 meters): modulating effects of caloric restriction. Am J Physiol Endocrinol Metab 2006; 290: E1078-E1088
  CrossrefPubMedGoogle Scholar
• 19 Maher JT, Jones LG, Hartley LH, Williams GH, Rose LI. Aldosterone dynamics during graded exercise at sea level and high altitude. J Appl Physiol 1975; 39: 18-22
  PubMedGoogle Scholar
• 20 Basu M, Pal K, Prasad R, Malhotra AS, Rao KS, Sawhney RC. Pituitary, gonadal and adrenal hormones after prolonged residence at extreme altitude in man. Int J Androl 1997; 20: 153-158
  CrossrefPubMedGoogle Scholar
• 21 Savourey G, Garcia N, Caravel JP, Gharib C, Pouzeratte N, Martin S, Bittel J. Pre-adaptation, adaptation and de-adaptation to high altitude in humans: hormonal and biochemical changes at sea level. Eur J Appl Physiol 1998; 77: 37-43
  PubMedGoogle Scholar
• 22 Benso A, Broglio F, Aimaretti G, Lucatello B, Lanfranco F, Ghigo E, Grottoli S. Endocrine and metabolic responses to extreme altitude and physical exercise in climbers. Eur J Endocrin 2007; 157: 733-740
  CrossrefPubMedGoogle Scholar
• 23 Chen SM, Wang JS, Lee WC, Hou CW, Chen CY, Laio YH, Lin CH, Kuo CH. Validity of the 3 min step test in moderate altitude: environmental temperature as a confounder. Apply Physiol Nutr Metab 2006; 31: 726-730
  PubMedGoogle Scholar
• 24 Ellsworth AJ, Larson EB, Strickland D. A randomized trial of dexamethasone and acetazolamide for acute mountain sickness prophylaxis. Am J Med 1987; 83: 1024-1030
  CrossrefPubMedGoogle Scholar
• 25 Basu M, Sawhney RC, Kumar S, Pal K, Prasad R, Selvamurthy W. Hypothalamic-pituitary-adrenal axis following glucocorticoid prophylaxis against acute mountain sickness. Horm Metab Res 2002; 34: 318-324
  Article in Thieme ConnectPubMedGoogle Scholar
• 26 Hackett PH, Roach RC, Wood RA, Foutch RG, Meehan RT, Rennie D, Mills Jr WJ. Dexamethasone for prevention and treatment of acute mountain sickness. Aviat Space Environ Med 1988; 59: 950-954
  PubMedGoogle Scholar
• 27 Levine BD, Yoshimura K, Kobayashi T, Fukushima M, Shibamoto T, Ueda G. Dexamethasone in the treatment of acute mountain sickness. N Engl J Med 1989; 321: 1707-1713
  CrossrefPubMedGoogle Scholar
• 28 Garde AH, Hansen AM. Long-term stability of salivary cortisol. Scand J Clin Lab Invest 2005; 65: 433-436
  CrossrefPubMedGoogle Scholar
• 29 Hackett PH, Oelz O. The Lake Louise consensus on the quantification of altitude illness. In: Sutton JR, Houston CS, Coates G. (eds.). Hypoxia and Mountain Medicine. Burlington, VT: Queen City Printers; 1992: 327-330
  Google Scholar
• 30 Eijsbouts AM, Kempers MJ, Kramer RS, Hopman MT, van den Hoogen FH, Laan RF, Hermus AR, Sweep FC, van de Putte LB. Effect of naproxen on the hypothalamic-pituitary-adrenal axis in healthy volunteers. Br J Clin Pharmacol 2009; 67: 22-28
  CrossrefPubMedGoogle Scholar
• 31 Smith TJ, Grediagin A, Kellogg MD, Muza SR, Friedlander AL, Cymerman A, Young AJ. Salivary Cortisol Response in Physically Active Males at High Altitude (4 300 M). Med Sci Sports Exercise 2004; 36: S108
  PubMedGoogle Scholar
• 32 Smith JD, Cianflone K, Martin J, Poirier P, Broderick TL, Noël M. Plasma adipokine and hormone changes in mountaineers on ascent to 5 300 meters. Wilderness Environ Med 2011; 22: 107-114
  CrossrefPubMedGoogle Scholar
• 33 Milledge JS, Catley DM, Williams ES, Withey WR, Minty BD. Effect of prolonged exercise at altitude on the renin-aldosterone system. J Appl Physiol 1983; 55: 413-418
  PubMedGoogle Scholar
• 34 Bouissou P, Richalet JP, Galen FX, Lartigue M, Larmignat P, Devaux F, Dubray C, Keromes A. Effect of beta-adrenoceptor blockade on renin-aldosterone and alpha-ANF during exercise at altitude. J Appl Physiol 1989; 67: 141-146
  PubMedGoogle Scholar
• 35 Bouissou P, Fiet J, Guezennec CY, Pesquies PC. Plasma adrenocorticotrophin and cortisol responses to acute hypoxia at rest and during exercise. Eur J Appl Physiol Occup Physiol 1988; 57: 110-113
  CrossrefPubMedGoogle Scholar
• 36 Tremblay MS, Copeland JL, Van Helder W. Effect of training status and exercise mode on endogenous steroid hormones in men. J Appl Physiol 2004; 96: 531-539
  CrossrefPubMedGoogle Scholar